Search Results | Molecular Cancer Therapeutics | American Association for Cancer Research

1-20 of 25

Sort by

Sort Order Select

Journal Articles

Development of highly effective anti-mesothelin hYP218 Chimeric Antigen Receptor T cells with increased tumor infiltration and persistence for treating solid tumors

Raffit Hassan, Sakshi Tomar, Jingli Zhang, Manakamana Khanal, Jessica Hong, Abhilash Venugopalan, Qun Jiang, Manjistha Sengupta, Markku Miettinen, Nan Li, Ira Pastan, Mitchell Ho

Mol Cancer Ther molcanther.MCT-22-0073-A.2022.

DOI: https://doi.org/10.1158/1535-7163.MCT-22-0073

Published: 02 May 2022

View article

Includes: Supplementary data

Journal Articles

GPC1-targeted immunotoxins inhibit pancreatic tumor growth in mice via depletion of short-lived GPC1 and downregulation of Wnt signaling

Jiajia Pan, Nan Li, Alex Renn, Hu Zhu, Lu Chen, Min Shen, Matthew D. Hall, Min Qian, Ira Pastan, Mitchell Ho

Mol Cancer Ther molcanther.0778.2021.

DOI: https://doi.org/10.1158/1535-7163.MCT-21-0778

Published: 21 March 2022

View article

Includes: Supplementary data

Journal Articles

Site-Specific PEGylation of Anti-Mesothelin Recombinant Immunotoxins Increases Half-life and Antitumor Activity

Zeliang Zheng, Ryuhei Okada, Hisataka Kobayashi, Tadanobu Nagaya, Junxia Wei, Qi Zhou, Fred Lee, Tapan K. Bera, Yun Gao, William Kuhlman, Chin-Hsien Tai, Ira Pastan

Mol Cancer Ther (2020) 19 (3): 812–821.

DOI: https://doi.org/10.1158/1535-7163.MCT-19-0890

Published: 02 March 2020

View article

Includes: Supplementary data

Journal Articles

Abstract CN07-03: Recombinant immunotoxins for hematologic malignancies

Robert Kreitman, Daniel Gorelik, Maryalice Stetler-Stevenson, Constance M Yuan, Hao-Wei Wang, Hong Zhou, Katherine Potocka, Erin Fykes, Evgeny Arons, Ira Pastan

Mol Cancer Ther (2019) 18 (12_Supplement): CN07-03.

DOI: https://doi.org/10.1158/1535-7163.TARG-19-CN07-03

Published: 01 December 2019

View article

Journal Articles

Abstract CN07-02: Immunotoxins targeting GPC3 for liver cancer

Mitchell Ho, Bryan D Fleming, Tim F Greten, Ira Pastan

Mol Cancer Ther (2019) 18 (12_Supplement): CN07-02.

DOI: https://doi.org/10.1158/1535-7163.TARG-19-CN07-02

Published: 01 December 2019

View article

Journal Articles

Abstract A081: Phase I study of mesothelin-targeted immunotoxin LMB-100 given as a long infusion

Christine Alewine, Mehwish Iqra Ahmad, Cody J Peer, Seth Steinberg, William D Figg, Raffit Hassan, Ira Pastan

Mol Cancer Ther (2019) 18 (12_Supplement): A081.

DOI: https://doi.org/10.1158/1535-7163.TARG-19-A081

Published: 01 December 2019

View article

Journal Articles

Improving the In Vivo Efficacy of an Anti-Tac (CD25) Immunotoxin by Pseudomonas Exotoxin A Domain II Engineering

Gilad Kaplan, Ronit Mazor, Fred Lee, Youjin Jang, Yasmin Leshem, Ira Pastan

Mol Cancer Ther (2018) 17 (7): 1486–1493.

DOI: https://doi.org/10.1158/1535-7163.MCT-17-1041

Published: 01 July 2018

View article

Includes: Supplementary data

Journal Articles

Reduced Shedding of Surface Mesothelin Improves Efficacy of Mesothelin-Targeting Recombinant Immunotoxins

Prince Awuah, Tapan K. Bera, Messan Folivi, Oleg Chertov, Ira Pastan

Mol Cancer Ther (2016) 15 (7): 1648–1655.

DOI: https://doi.org/10.1158/1535-7163.MCT-15-0863

Published: 05 July 2016

View article

Includes: Supplementary data

Journal Articles

Protein Kinase Inhibitor H89 Enhances the Activity of Pseudomonas Exotoxin A–Based Immunotoxins

Xiufen Liu, Fabian Müller, Alan S. Wayne, Ira Pastan

Mol Cancer Ther (2016) 15 (5): 1053–1062.

DOI: https://doi.org/10.1158/1535-7163.MCT-15-0828

Published: 05 May 2016

View article

Includes: Supplementary data

Journal Articles

Recombinant Immunotoxin with T-cell Epitope Mutations That Greatly Reduce Immunogenicity for Treatment of Mesothelin-Expressing Tumors

Ronit Mazor, Jingli Zhang, Laiman Xiang, Selamawit Addissie, Prince Awuah, Richard Beers, Raffit Hassan, Ira Pastan

Mol Cancer Ther (2015) 14 (12): 2789–2796.

DOI: https://doi.org/10.1158/1535-7163.MCT-15-0532

Published: 06 December 2015

View article

Includes: Supplementary data

Journal Articles

Abstract C163: Understanding the mechanism for synergistic anti-tumor activity of a meosthelin-targeted immunotoxin and taxanes

Christine Campo Alewine, Emily Kolyvas, Ira Pastan

Mol Cancer Ther (2015) 14 (12_Supplement_2): C163.

DOI: https://doi.org/10.1158/1535-7163.TARG-15-C163

Published: 01 December 2015

View article

Journal Articles

Abstract A157: Multi-kinase inhibitor H89 enhances activity of pseudomonas exotoxin-based immunotoxins targeting acute lymphoblastic leukemia

Fabian Mueller, Xiu Fen Liu, Alan S. Wayne, Ira Pastan

Mol Cancer Ther (2015) 14 (12_Supplement_2): A157.

DOI: https://doi.org/10.1158/1535-7163.TARG-15-A157

Published: 01 December 2015

View article

Journal Articles

Efficacy of RG7787, a Next-Generation Mesothelin-Targeted Immunotoxin, against Triple-Negative Breast and Gastric Cancers

Christine Alewine, Laiman Xiang, Takao Yamori, Gerhard Niederfellner, Klaus Bosslet, Ira Pastan

Mol Cancer Ther (2014) 13 (11): 2653–2661.

DOI: https://doi.org/10.1158/1535-7163.MCT-14-0132

Published: 03 November 2014

View article

Includes: Supplementary data

Journal Articles

In Vitro and In Vivo Activity of the Low-Immunogenic Antimesothelin Immunotoxin RG7787 in Pancreatic Cancer

Kevin Hollevoet, Emily Mason-Osann, Xiu-fen Liu, Sabine Imhof-Jung, Gerhard Niederfellner, Ira Pastan

Mol Cancer Ther (2014) 13 (8): 2040–2049.

DOI: https://doi.org/10.1158/1535-7163.MCT-14-0089-T

Published: 05 August 2014

View article

Includes: Supplementary data

Journal Articles

Antitumor Effects of Immunotoxins Are Enhanced by Lowering HCK or Treatment with Src Kinase Inhibitors

Xiu-Fen Liu, Laiman Xiang, David J. FitzGerald, Ira Pastan

Mol Cancer Ther (2014) 13 (1): 82–89.

DOI: https://doi.org/10.1158/1535-7163.MCT-13-0726

Published: 13 January 2014

View article

Includes: Supplementary data

Journal Articles

A Recombinant Immunotoxin against the Tumor-Associated Antigen Mesothelin Reengineered for High Activity, Low Off-Target Toxicity, and Reduced Antigenicity

John E. Weldon, Laiman Xiang, Jingli Zhang, Richard Beers, Dawn A. Walker, Masanori Onda, Raffit Hassan, Ira Pastan

Mol Cancer Ther (2013) 12 (1): 48–57.

DOI: https://doi.org/10.1158/1535-7163.MCT-12-0336

Published: 13 January 2013

View article

Includes: Supplementary data

Journal Articles

Mesothelin-Targeted Agents in Clinical Trials and in Preclinical Development

Ronan J. Kelly, Elad Sharon, Ira Pastan, Raffit Hassan

Mol Cancer Ther (2012) 11 (3): 517–525.

DOI: https://doi.org/10.1158/1535-7163.MCT-11-0454

Published: 06 March 2012

View article

Journal Articles

Interstitial Infusion of Glioma-Targeted Recombinant Immunotoxin 8H9scFv-PE38

Neal Luther, Nai-Kong Cheung, Eleni P. Souliopoulos, Ioannis Karempelas, Daniel Bassiri, Mark A. Edgar, Hong-fen Guo, Ira Pastan, Philip H. Gutin, Mark M. Souweidane

Mol Cancer Ther (2010) 9 (4): 1039–1046.

DOI: https://doi.org/10.1158/1535-7163.MCT-09-0996

Published: 07 April 2010

View article

Journal Articles

A novel human monoclonal antibody that binds with high affinity to mesothelin-expressing cells and kills them by antibody-dependent cell-mediated cytotoxicity

Yang Feng, Xiaodong Xiao, Zhongyu Zhu, Emily Streaker, Mitchell Ho, Ira Pastan, Dimiter S. Dimitrov

Mol Cancer Ther (2009) 8 (5): 1113–1118.

DOI: https://doi.org/10.1158/1535-7163.MCT-08-0945

Published: 13 May 2009

View article

Journal Articles

FCRL1 on chronic lymphocytic leukemia, hairy cell leukemia and B-cell non-Hodgkin's lymphoma as a target of immunotoxins

Xing Du, Satoshi Nagata, Tomoko Ise, Maryalice Stetler-Stevenson, Ira Pastan

Mol Cancer Ther (2007) 6 (11_Supplement): A55.

Published: 01 November 2007

View article

NARROW

Development of highly effective anti-mesothelin hYP218 Chimeric Antigen Receptor T cells with increased tumor infiltration and persistence for treating solid tumors

GPC1-targeted immunotoxins inhibit pancreatic tumor growth in mice via depletion of short-lived GPC1 and downregulation of Wnt signaling

Site-Specific PEGylation of Anti-Mesothelin Recombinant Immunotoxins Increases Half-life and Antitumor Activity

Abstract CN07-03: Recombinant immunotoxins for hematologic malignancies

Abstract CN07-02: Immunotoxins targeting GPC3 for liver cancer

Abstract A081: Phase I study of mesothelin-targeted immunotoxin LMB-100 given as a long infusion

Improving the In Vivo Efficacy of an Anti-Tac (CD25) Immunotoxin by Pseudomonas Exotoxin A Domain II Engineering

Reduced Shedding of Surface Mesothelin Improves Efficacy of Mesothelin-Targeting Recombinant Immunotoxins

Protein Kinase Inhibitor H89 Enhances the Activity of Pseudomonas Exotoxin A–Based Immunotoxins

Recombinant Immunotoxin with T-cell Epitope Mutations That Greatly Reduce Immunogenicity for Treatment of Mesothelin-Expressing Tumors

Abstract C163: Understanding the mechanism for synergistic anti-tumor activity of a meosthelin-targeted immunotoxin and taxanes

Abstract A157: Multi-kinase inhibitor H89 enhances activity of pseudomonas exotoxin-based immunotoxins targeting acute lymphoblastic leukemia

Efficacy of RG7787, a Next-Generation Mesothelin-Targeted Immunotoxin, against Triple-Negative Breast and Gastric Cancers

In Vitro and In Vivo Activity of the Low-Immunogenic Antimesothelin Immunotoxin RG7787 in Pancreatic Cancer

Antitumor Effects of Immunotoxins Are Enhanced by Lowering HCK or Treatment with Src Kinase Inhibitors

A Recombinant Immunotoxin against the Tumor-Associated Antigen Mesothelin Reengineered for High Activity, Low Off-Target Toxicity, and Reduced Antigenicity

Mesothelin-Targeted Agents in Clinical Trials and in Preclinical Development

Interstitial Infusion of Glioma-Targeted Recombinant Immunotoxin 8H9scFv-PE38

A novel human monoclonal antibody that binds with high affinity to mesothelin-expressing cells and kills them by antibody-dependent cell-mediated cytotoxicity

FCRL1 on chronic lymphocytic leukemia, hairy cell leukemia and B-cell non-Hodgkin's lymphoma as a target of immunotoxins

Email alerts

AACR Journals

Email alerts

AACR Journals

This Feature Is Available To Subscribers Only